Efficacy of a novel oral carbapenem, tebipenem pivoxil (TBM-PI), against experimental otitis media caused by penicillin resistant Streptococcus pneumoniae in chinchilla.
An animal model of otitis media using chinchillas was developed to evaluate the efficacy of tebipenem pivoxil (TBM-PI) against experimental otitis media. Chinchillas inoculated via the transbullar approach with Streptococcus pneumoniae serogroup 6 were included in the efficacy study with TBM-PI, amoxicillin (AMX) or untreated as controls. TBM-PI resulted in survival rate of 83%, compared with 25% survival for AMX and 0% survival for controls (p<0.01). Quantitative cultures in the middle ear effusions at day 5 of the TBM-PI group yielded 3.5+/-2.4log(10)CFUs/ml. TBM-PI is a promising antibiotic for the treatment of acute otitis media.
Hotomi
Muneki
M
Infection and Immunity Research Center, Wakayama Medical University, Wakayama, Japan.
Suzumoto
Masaki
M
Itahashi
Koju
K
Nagura
Jun
J
Fukushima
Takayoshi
T
Shimada
Jun
J
Billal
Dewan S
DS
Yamauchi
Kazuma
K
Fujihara
Keiji
K
Yamanaka
Noboru
N
D000284:Administration, Oral; D000658:Amoxicillin / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D015780:Carbapenems / Q000493:pharmacokinetics / Q000494:pharmacology*; D002682:Chinchilla; D008297:Male; D023421:Models, Animal; D010033:Otitis Media / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D010403:Penicillin Resistance; D011008:Pneumococcal Infections / Q000188:drug therapy* / Q000378:metabolism; D013296:Streptococcus pneumoniae / Q000302:isolation & purification*
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000658:Amoxicillin; C500135:tebipenem